Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003150 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
A Phase 3 study of Lymphoma, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
- 20
- Study locations
NCT00003150: Completed Phase 3 study of Lymphoma, sponsored by Eastern Cooperative Oncology Group.
NCT00003150 is a Phase 3 study of Lymphoma that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 630 participants, above the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003150, a Phase 3 study of Lymphoma, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if combination chemotherapy is more effective with or without rituximab for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without rituximab in treating older patients who have non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG doxorubicin hydrochloride
- DRUG CHOP regimen
Study Locations (20)
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- Veterans Affairs Medical Center - Long Beach - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Medical Center - Sacramento
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- David Grant Medical Center - Travis Air Force Base
Arizona
- CCOP - Greater Phoenix - Phoenix
- Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Colorado
- University of Colorado Cancer Center - Denver
- Veterans Affairs Medical Center - Denver - Denver
Alabama
- MBCCOP - Gulf Coast - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 1997-12 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00003150 record still lists
NCT00003150 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, above the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (31% higher).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT00003150 names 20 study sites across 5 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00003150 about?
NCT00003150 is a clinical study titled "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known i...
What is the current status of trial NCT00003150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 1997-12. Estimated completion is 2006-09.
What conditions does trial NCT00003150 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00003150?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), rituximab (BIOLOGICAL), doxorubicin hydrochloride (DRUG), CHOP regimen (DRUG).
Who is sponsoring clinical trial NCT00003150?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003150 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003150's enrollment target sits among peer trials
630 12th of 299 higher than 288 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia